Drug intelligence / Profile preview

AKP-017

Development stage: Preclinical
Lead developer: ASKA Pharmaceutical
Modality: Small Molecules
Administration: Intranasal

Overview

AKP-017 is an intranasal small molecule formulation of testosterone being developed by ASKA Pharmaceutical. As a hormone preparation administered via the transnasal route, it is designed for the treatment of urological conditions. The transnasal delivery method is typically intended to provide efficient absorption and avoid first-pass metabolism associated with oral administration. As of early 2026, the drug is in the preparation stage for clinical trials, representing a key part of ASKA Pharmaceutical's urology pipeline.

Other names: transnasal testosterone

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on AKP-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKP-017.

Explore the full profile